FDA Approves SOHONOS — Ipsen Biopharmaceuticals, Inc.

Ipsen Biopharmaceuticals, Inc. announced FDA approval of palovarotene soft capsules (Sohonos), intended for pediatric patients with amenable ichthyoses, which establishes a novel therapeutic niche within the rare ophthalmology and dermatology markets. The approval is expected to bolster Ipsen’s revenue pipeline by expanding its portfolio into a high-need area that lacks widely accepted treatments, though the company will need to strategically manage the complex challenges associated with OXCT2-related and non-OXCT2-related fibrostenotic skeletal abnormalities.